Anguita-Sánchez, ManuelMarco-Vera, PascualAlonso-Moreno, Francisco JArribas-Ynsaurriaga, FernandoGállego-Culleré, JaimeHonorato-Pérez, JesúsSuárez-Fernández, CarmenInvestigadores del estudio ACADEMIC2023-01-252023-01-252016-03-10http://hdl.handle.net/10668/9914Recent studies have demonstrated the efficacy and safety of new oral anticoagulant drugs for the prevention of thromboembolic events in patients with non-valvular atrial fibrillation. Our aim was to evaluate the factors that can influence physicians in their choice between a classic and a new anticoagulant in these patients. Several variables of interest were discussed and analysed using a WorkmatTM methodology. Six regional meetings were held in Spain (East, Catalonia, Andalusia-Extremadura, Madrid, North-east, and North of Spain). Meetings were attended by 39 specialists (cardiologists, neurologists, haematologists, internists, and emergency and Primary Care physicians). Each participant graded their level of agreement, with a score from 1 to 10, on every analysed variable. A new anticoagulant drug was preferred in patients with previous failure of dicoumarin therapy (9.7±0.5), high haemorrhagic risk (8.7±1), prior bleeding (7.8±1.5), and high thrombotic risk (7.7±1.2). Dicoumarins were preferred in cases of severe (1.2±0.4) or moderate (4.2±2.5) kidney failure, good control with dicoumarins (2.3±1.5), cognitive impairment (3.2±3), and low haemorrhagic risk (4.3±3). Age, sex, weight, cost of drug, polymedication, and low thrombotic risk achieved intermediate scores. There were no differences between the different specialists or Spanish regions. The presence of a high thrombotic or haemorrhagic risk and the failure of previous dicoumarin therapy lead to choosing a new oral anticoagulant in patients with non-valvular atrial fibrillation, while kidney failure, cognitive impairment, good control with dicoumarins, and a low bleeding risk predispose to selecting a classic dicoumarin anticoagulant.esAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Anticoagulantes oralesAnticoagulantsAtrial fibrillationEmboliaEmbolismsFibrilación auricularAnticoagulantsAtrial FibrillationDicumarolHumansPractice Patterns, Physicians'SpainStrokeThromboembolismresearch article26971361open access10.1016/j.aprim.2015.11.0041578-1275PMC6877842https://doi.org/10.1016/j.aprim.2015.11.004https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877842/pdf